45 results on '"Reipert, Birgit M."'
Search Results
2. Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 study
3. Prospective hemophilia inhibitor PUP study reveals distinct antibody signatures during FVIII inhibitor eradication
4. Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors
5. BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression
6. AAV8-Specific Immune Adsorption Column: A Treatment Option for Patients with Pre-Existing Anti-AAV8 Neutralizing Antibodies
7. The Factor VIII Variant X5 Enhances Hemophilia a Gene Therapy Efficiency By Its Improved Secretion
8. Data Coming out of the Human Inhibitor PUP Study (HIPS) Reveal 4 Subgroups of Patients with Distinct Antibody Signatures
9. The Irish Personalized Approach to the Treatment of Haemophilia (iPATH) - Determinants of Inter-Individual Variation in FVIII Pharmacokinetics
10. Appearance of High-Affinity Antibodies Precedes Clinical Diagnosis of FVIII Inhibitors - Preliminary Analysis from the Hemophilia Inhibitor PUP Study (HIPS)
11. Immunogenicity of BAX 855 in Previously Treated Patients with Congenital Severe Hemophilia Α
12. FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors
13. Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A
14. Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans
15. Administration of Dexamethasone during Initial Exposure to Factor VIII Induces Durable and Antigen-Specific Tolerance to Factor VIII in Hemophilia Α Mice with a Humanized Major Histocompatibility Complex II Transgene
16. Immunization Against Influenza but Not MMR Modulates the Anti-Factor VIII Immune Response in Hemophilia Α Mice
17. Risky business of inhibitors: HLA haplotypes, gene polymorphisms, and immune responses
18. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients
19. Surgical Injury Alone Does Not Provoke the Development of Factor VIII Inhibitors in Mouse Models of Hemophilia A
20. CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice
21. Preclinical Immunogenicity Assessment of Baxter‘s Recombinant Factor VIIa,
22. Preclinical Immunogenicity Assessment of Baxter‘s Longer-Acting FVIII Candidate BAX 855 Using Novel Preclinical Models,
23. Deciphering of CD4+ T Cell Subsets Involved in Maintenance and Break of Immune Tolerance in a Humanized Mouse Model That Is Immune Tolerant to Human FVII
24. Induction and Break of Immune Tolerance to Human FVIII in a HLA-DRB1*1501 Humanized Hemophilic Mouse Model
25. Maintenance and break of immune tolerance against human factor VIII in a new transgenic hemophilic mouse model
26. T cell–independent restimulation of FVIII-specific murine memory B cells is facilitated by dendritic cells together with toll-like receptor 7 agonist
27. Stimulation and inhibition of FVIII-specific memory B-cell responses by CpG-B (ODN 1826), a ligand for Toll-like receptor 9
28. New Early Prophylaxis Regimen That Avoids Immunological Danger Signals Can Reduce Factor Eight (FVIII) Inhibitor Development Independent From Product Type Used.
29. Agonist for Toll-Like Receptor (TLR) 9 Amplifies as Well as Inhibits the Differentiation of FVIII-Specific Memory B Cells into Antibody-Producing Plasma Cells in Vitro and in Vivo.
30. Requirements for Co-Stimulation in T-Cell Dependent and T-Cell Independent Re-Stimulation of FVIII-Specific Memory B Cells
31. Immune Tolerance to Human Factor VIII Induced by Liver-Specific Expression of a Human Factor VIII Transgene in Hemophilic Mice.
32. The Relevance of the Inhibitory Receptor FcγIIB for the Regulation of Anti-Factor VIII Antibody Responses in Murine Models.
33. T-Cell-Independent Re-Stimulation of FVIII-Specific Memory B Cells Requires Help from Activated Plasmacytoid Dendritic Cells.
34. Single-Cell Analysis of FVIII-Specific Memory B Cells in Murine Hemophilia A.
35. Humanized E17 Hemophilic Mice Are a Major Breakthrough in the Design of New Preclinical Models for Developing Factor VIII Products with Reduced Immunogenicity.
36. Naturally Occurring Regulatory T Cells Modulate Immune Responses Against Exogenous Factor VIII in Hemophilic Balb/c Mice but Not in C57BL/6J Mice.
37. Tracking Factor VIII-Specific Memory B Cells in Hemophilia A Patients with Factor VIII Inhibitors.
38. Comparable Long-Term Persistence of Anti-FVIII Antibodies in Hemophilic E17 Mice on Different Genetic Backgrounds Despite Significant Differences in the Amplitude of the Immune Responses.
39. Toll-Like Receptor Triggering Modulates Factor VIII-Specific Immune Memory in Murine Hemophilia A with Factor VIII Inhibitors.
40. High-dose factor VIII inhibits factor VIII–specific memory B cells in hemophilia A with factor VIII inhibitors
41. Inhibition of Factor VIII-Specific Memory B Cell Responses by Supra-Physiological Concentrations of Factor VIII.
42. Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders
43. Anti–factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study.
44. CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVHI in humanized hemophilic E17 HLA-DRB1*1501 mice.
45. Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.